Literature DB >> 22921769

The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons.

N Murataeva1, K Mackie, A Straiker.   

Abstract

The G protein coupled receptors CB(1) and CB(2) are targets for the psychoactive constituents of cannabis, chief among them Δ(9)-THC. They are also key components of the multifunctional endogenous cannabinoid signaling system. CB(1) and CB(2) receptors modulate a wide variety of physiological systems including analgesia, memory, mood, reward, appetite and immunity. Identification and characterization of selective CB(1) and CB(2) receptor agonists and antagonists will facilitate understanding the precise physiological and pathophysiological roles of cannabinoid receptors in these systems. This is particularly necessary in the case of CB(2) because these receptors are sparsely expressed and problematic to detect using traditional immunocytochemical approaches. 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH015) is an aminoalkylindole that has been employed as a "CB(2)-selective" agonist in more than 40 published papers. However, we have found that JWH015 potently and efficaciously activates CB(1) receptors in neurons. Using murine autaptic hippocampal neurons, which express CB(1), but not CB(2) receptors, we find that JWH015 inhibits excitatory postsynaptic currents with an EC50 of 216nM. JWH015 inhibition is absent in neurons from CB(1)(-/-) cultures and is reversed by the CB(1) antagonist, SR141716 [200nM]. Furthermore, JWH015 partially occludes CB(1)-mediated DSE (∼35% remaining), an action reversed by the CB(2) antagonist, AM630 [1 and 3μM], suggesting that high concentrations of AM630 also antagonize CB(1) receptors. We conclude that while JWH015 is a CB(2)-preferring agonist, it also activates CB(1) receptors at experimentally encountered concentrations. Thus, CB(1) agonism of JWH015 needs to be considered in the design and interpretation of experiments that use JWH015 to probe CB(2)-signaling.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22921769      PMCID: PMC3601544          DOI: 10.1016/j.phrs.2012.08.002

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  42 in total

1.  Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture.

Authors:  J M Bekkers; C F Stevens
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

2.  Characterization and partial purification of AIM: a plasma protein that induces rat cerebral type 2 astroglia from bipotential glial progenitors.

Authors:  S W Levison; K D McCarthy
Journal:  J Neurochem       Date:  1991-09       Impact factor: 5.372

3.  The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells.

Authors:  Takayuki Yoshida; Kouichi Hashimoto; Andreas Zimmer; Takashi Maejima; Kenji Araishi; Masanobu Kano
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

4.  Localization of cannabinoid receptor mRNA in rat brain.

Authors:  L A Matsuda; T I Bonner; S J Lolait
Journal:  J Comp Neurol       Date:  1993-01-22       Impact factor: 3.215

5.  Synthesis and pharmacology of a hybrid cannabinoid.

Authors:  J W Huffman; J Lu; D Dai; A Kitaygorodskiy; J L Wiley; B R Martin
Journal:  Bioorg Med Chem       Date:  2000-02       Impact factor: 3.641

6.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA.

Authors:  L A Matsuda; S J Lolait; M J Brownstein; A C Young; T I Bonner
Journal:  Nature       Date:  1990-08-09       Impact factor: 49.962

7.  Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding.

Authors:  M M Aung; G Griffin; J W Huffman; M Wu; C Keel; B Yang; V M Showalter; M E Abood; B R Martin
Journal:  Drug Alcohol Depend       Date:  2000-08-01       Impact factor: 4.492

8.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

9.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

Authors:  W A Devane; L Hanus; A Breuer; R G Pertwee; L A Stevenson; G Griffin; D Gibson; A Mandelbaum; A Etinger; R Mechoulam
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

10.  Chemical transmission between rat sympathetic neurons and cardiac myocytes developing in microcultures: evidence for cholinergic, adrenergic, and dual-function neurons.

Authors:  E J Furshpan; P R MacLeish; P H O'Lague; D D Potter
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

View more
  15 in total

1.  Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein.

Authors:  Changqing Xu; Douglas J Hermes; Blessing Nwanguma; Ian R Jacobs; Kenneth Mackie; Somnath Mukhopadhyay; Aron H Lichtman; Bogna Ignatowska-Jankowska; Sylvia Fitting
Journal:  Mol Cell Neurosci       Date:  2017-07-19       Impact factor: 4.314

2.  Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.

Authors:  Amey Dhopeshwarkar; Natalia Murataeva; Alex Makriyannis; Alex Straiker; Ken Mackie
Journal:  J Pharmacol Exp Ther       Date:  2016-12-07       Impact factor: 4.030

Review 3.  CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?

Authors:  Amey Dhopeshwarkar; Ken Mackie
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

4.  CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice.

Authors:  Ramy Khella; Jennifer L Short; Daniel T Malone
Journal:  Psychopharmacology (Berl)       Date:  2014-04-05       Impact factor: 4.530

Review 5.  The endocannabinoid system - a target for the treatment of LUTS?

Authors:  Petter Hedlund; Christian Gratzke
Journal:  Nat Rev Urol       Date:  2016-07-05       Impact factor: 14.432

6.  Antinociceptive effects of JWH015 in female and male rats.

Authors:  Rebecca M Craft; Nicholas Z Greene; Alexa A Wakley
Journal:  Behav Pharmacol       Date:  2018-04       Impact factor: 2.293

7.  Activation of type-2 cannabinoid receptor inhibits neuroprotective and antiinflammatory actions of glucocorticoid receptor α: when one is better than two.

Authors:  Elisa Bisicchia; Valerio Chiurchiù; Maria Teresa Viscomi; Laura Latini; Filomena Fezza; Luca Battistini; Mauro Maccarrone; Marco Molinari
Journal:  Cell Mol Life Sci       Date:  2013-01-08       Impact factor: 9.261

8.  Cannabinoid-induced chemotaxis in bovine corneal epithelial cells.

Authors:  Natalia Murataeva; Shimin Li; Olivia Oehler; Sally Miller; Amey Dhopeshwarkar; Sherry Shu-Jung Hu; Joseph A Bonanno; Heather Bradshaw; Ken Mackie; Douglas McHugh; Alex Straiker
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

Review 9.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

10.  The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects.

Authors:  Lirit N Franks; Benjamin M Ford; Toshifumi Fujiwara; Haibo Zhao; Paul L Prather
Journal:  Toxicol Appl Pharmacol       Date:  2018-06-12       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.